Recent Updates
Recently added Catalysts
ABT

Abbott and AstraZeneca End License Agreement for the Development of CERTRIAD™ Abbott (NYSE: ABT) announced today that Abbott and AstraZeneca will discontinue their joint collaboration for the development of CERTRIAD™...

Key Takeaway: There will be no financial impact to Abbott's ongoing earnings per share in 2010 or 2011 resulting from this action. Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, incl

Full Press Release Details

There will be no financial impact to Abbott's ongoing earnings per share in 2010 or 2011 resulting from this action.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at www.abbott.com .

21 %

Last updated: Dec 22, 2010